Somanta signs cancer drug-development agreement with University of Bradford

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Somanta Pharmaceuticals has signed a research collaboration agreement with the University of Bradford, United Kingdom, giving Somanta the rights to new data, inventions and discoveries in certain areas of cancer research at the University's Institute for Cancer Therapeutics.

As part of the agreement, the Irvine, Calif., oncology company said the Institute for Cancer Therapeutics will also continue development work on two of Somanta's pre-clinical cancer drugs, Alchemix and Prodrax.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.